Your browser doesn't support javascript.
Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles
Kei Miyakawa; Sundararaj Stanleyraj Jeremiah; Norihisa Ohtake; Satoko Matsunaga; Yutaro Yamaoka; Mayuko Nishi; Takeshi Morita; Ryo Saji; Mototsugu Nishii; Hirokazu Kimura; Hideki Hasegawa; Ichiro Takeuchi; Akihide Ryo.
  • Kei Miyakawa; Yokohama City University School of Medicine
  • Sundararaj Stanleyraj Jeremiah; Yokohama City University School of Medicine
  • Norihisa Ohtake; Yokohama City University
  • Satoko Matsunaga; Yokohama City University School of Medicine
  • Yutaro Yamaoka; Kanto Chemical Co., Inc.
  • Mayuko Nishi; Yokohama City University School of Medicine
  • Takeshi Morita; Yokohama City University School of Medicine
  • Ryo Saji; Yokohama City University Hospital
  • Mototsugu Nishii; Yokohama City University Hospital
  • Hirokazu Kimura; Gunma Paz University
  • Hideki Hasegawa; National Institute of Infectious Diseases
  • Ichiro Takeuchi; Yokohama City University Hospital
  • Akihide Ryo; Yokohama City University School of Medicine
Preprint in English | medRxiv | ID: ppmedrxiv-20158410
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
SARS-CoV-2 neutralizing antibodies confer protective immunity against reinfection. We have developed a rapid test for screening SARS-CoV-2 neutralization antibodies using genome-free virus-like particles incorporated with a small luciferase peptide, HiBiT. Their entry into LgBiT-expressing target cells reconstitutes NanoLuc luciferase readily detected by a luminometer. This newly developed HiBiT-tagged Virus-like particle-based Neutralization Test (hiVNT) can readily quantify SARS-CoV-2 neutralizing antibodies within three hours with a high-throughput in a low biosafety setting. Moreover, the neutralizing activity obtained from hiVNT was highly consistent with that measured by the conventional neutralization test using authentic SARS-CoV-2. Furthermore, antibody responses to both viral spike and nucleocapsid proteins correlated with the neutralization activity assessed by hiVNT. Our newly-developed hiVNT could be instrumental to survey individuals for the presence of functional neutralizing antibody against SARS-CoV-2.
Full text: Available Collection: Preprints Database: medRxiv Type of study: Diagnostic study / Screening study Language: English Year: 2020 Document Type: Preprint

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Collection: Preprints Database: medRxiv Type of study: Diagnostic study / Screening study Language: English Year: 2020 Document Type: Preprint